Overview of Regulatory Milestone
On March 6, 2026, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). This approval marks a significant expansion for the drug, which was originally approved in 2022 for moderate-to-severe plaque psoriasis.
Therapeutic Innovation: First-in-Class TYK2 Inhibitor
Mechanism of Action: Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor.
Market Position: It is the first and only TYK2 inhibitor approved for the treatment of psoriatic arthritis, offering a differentiated oral mechanism compared to existing biologics or JAK inhibitors.
Clinical Trial Foundation: POETYK PsA-1 and PsA-2
The approval is supported by positive data from two pivotal Phase 3 clinical trials evaluating a 6 mg once-daily dose of Sotyktu in adults with active PsA.
Primary Endpoint: ACR20 Response
In both trials, Sotyktu demonstrated a statistically significant improvement in disease activity compared to placebo at Week 16, as measured by the American College of Rheumatology (ACR) 20 response.
Secondary Endpoint: Minimal Disease Activity (MDA)
The trials also met the key secondary endpoint of Minimal Disease Activity (MDA), confirming the drug's efficacy in achieving low levels of disease manifestation across multiple clinical markers.
Impact on Health-Related Quality of Life
Clinical data highlighted improvements in patient-reported outcomes using the 36-Item Short Form Health Survey (SF-36):
Physical Component Summary (PCS): Patients treated with Sotyktu showed significant improvements in the SF-36 PCS score at Week 16.
Domain Improvements: Success was noted across all four PCS domains:
Physical functioning
Role-physical
Bodily-pain
General health
Safety Profile and Tolerability
The safety profile of Sotyktu in the psoriatic arthritis population was found to be generally consistent with its established profile in plaque psoriasis.
Common Adverse Reactions (≥1%)
Upper respiratory infections
Increased blood creatine phosphokinase (CPK)
Herpes simplex and folliculitis
Mouth ulcers and acne
Warnings and Precautions
The prescribing information includes warnings regarding:
Hypersensitivity reactions and serious infections (including Tuberculosis).
Malignancies (including lymphomas).
Rhabdomyolysis and elevated CPK levels.
Potential risks shared with the JAK inhibitor class.
About Psoriatic Arthritis (PsA)
Psoriatic arthritis is a chronic, systemic autoimmune disease affecting approximately 30% of patients with psoriasis. It is characterized by:
Musculoskeletal Manifestations: Inflammatory arthritis, enthesitis, and dactylitis.
Skin/Nail Involvement: Psoriatic lesions and nail dystrophy.
Patient Burden: Significant impairment in physical function, chronic pain, and fatigue.
